EAP-Combination Yervoy and Opdivo

The primary objective of this study is to provide treatment with nivolumab for the combination with ipilimumab (Yervoy) to subjects who are anti-CTLA-4 and anti-PD-1 treatment-naive and have unresectable or metastatic melanoma. Safety data will be collected and reported according to health authority regulations and BMS regulations. QoL data will be measured using the EORTC QLQ-C30. Additionally, survival data collection (up to 5 years following the subject¡¦s start of treatment with nivolumab) is recommended to be part of the subject¡¦s follow up and will be summarized or listed, depending on the extent of such collected data

September 25, 2015